Current trends in prostate cancer diagnosis and staging among United States urologists

Journal of Urology

Volumn 158, Issue 5, 1997, Pages 1853-1858

  Plawker, Marc W ^a   Fleisher, Jay M ^a   Vapnek, Evan M ^a   Macchia, Richard J ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BONE SCINTISCANNING; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPHADENECTOMY; MEDICAL PRACTICE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RESIDENCY EDUCATION; SCORING SYSTEM; UNITED STATES;

EID: 0030820022     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64145-4     Document Type: Article

References (49)

1. Plawker, M. W., Fleisher, J. M., Nitti, V. W. and Macchia, R. J.: Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer. J. Urol., 155: 601, 1996.
2. Baker, L. H., Hanks, G., Gershenson, D., Kantoff, P., Lange, P., Logothetis, C., Sandier, H. and Walsh, P. C.: NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Supp.), 10: 265, 1996.
3. Catalona, W. J. and Bigg, S. W.: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J. Urol., 143: 538, 1990.
4. Wahle, S., Reznicek, M., Fallon, B., Platz, C. and Williams, R.: Incidence of surgical margin involvement in various forms of prostatectomy. Urology, 36: 23, 1990.
5. Ackerman, D. A., Barry, J. M., Wichlund, R. A., Olson, N. and Lowe, B. A.: Analysis of risk factors associated with prostate cancer local extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol., 150: 1845, 1993.
6. Chodak, G. W.: Questioning the value of screening for prostate cancer in asymptomatic men. Urology, 42: 116, 1993.
7. Oesterling, J. E., Jacobson, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. A.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age specific reference ranges. J.A.M.A., 270: 860, 1993.
8. Anderson, J. R., Strickland, D., Corbin, D., Byrnes, J. A. and Zweiback, E.: Age-specific reference ranges for serum prostate-specific antigen. Urology, 46: 54, 1995.
9. el-Galley, R. E., Petros, J. A., Sanders, W. H., Keane, T. E., Galloway, N. T., Cooner, W. H. and Graham, S. D., Jr.: Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology, 46: 200, 1995.
10. Reissigl, A., Pointner, J., Horninger, W., Ennemoser, O., Strasser, H., Klocker, H. and Bartsch, G.: Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology, 46: 662, 1995.
11. Benson, M. C., Whang, I. S., Olsson, C. A., McMahon, D. J. and Cooner, W. H.: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol., part 2, 147: 817, 1992.
12. Brawer, M. K., Aramburu, E. A. G., Chen, G. L., Preston, S. D. and Ellis, W. J.: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J. Urol., 150: 369, 1993.
13. Ohori, M., Dunn, J. K. and Scardino, P. T.: Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology, 46: 666, 1995.
14. Hodge, K. K., McNeal, J. E., Terris, M. K. and Stamey, T. A.: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol., 142: 71, 1989.
15. Terris, M. K., McNeal, J. E. and Stamey, T. A.: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J. Urol., 148: 829, 1992.
16. Hammerer, P. and Huland, H.: Systematic sextant biopsies in 651 patients referred for prostate evaluation. J. Urol., 151: 99, 1994.
17. Lui, P. D., Terris, M. K., McNeal, J. E. and Stamey, T. A.: Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. J. Urol., part 2, 153: 1000, 1995.
18. Fowler, J. E., Jr., Condon, M. A. and Terrell, F. L.: Cancer diagnosis with prostate specific antigen greater than 10 ng./ ml. and negative peripheral zone prostate biopsy. J. Urol., 156: 1370, 1996.
19. Bazinet, M., Karakiewicz, P. I., Aprikian, A. G., Trudel, C., Aronson, S., Nachabé, M., Peloquin, F., Dessureault, J., Goyal, M., Zheng, W., Bégin, L. R. and Elhilali, M. M.: Value of systematic transition zone biopsies in the early detection of prostate cancer. J. Urol., 155: 605, 1996.
20. McNeal, J. E. and Noldus, J.: Limitations of transition zone needle biopsy findings in the prediction of transition zone cancer and tissue composition of benign nodular hyperplasia. Urology, 48: 751, 1996.
21. Campbell, S. C., Klein, E. A., Levin, H. S. and Piedmonte, M. R.: Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology, 46: 352, 1995.
22. Petros, J. A. and Catalona, W. J.: Low incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J. Urol., 147: 1574, 1992.
23. Bluestein, D. L., Bostwick, D. G., Bergstralh, E. J. and Oesterling, J. E.: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol., 151: 1315, 1994.
24. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
25. Smith, D. S. and Catalona, W. J.: The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol., 152: 1732, 1994.
26. Flanigan, R. C., McKay, T. C., Olson, M., Shankey, T. V., Pyle, J. and Waters, W. B.: Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology, 48: 428, 1996.
27. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vesella, R. L. and Lange, P. H.: Screening for prostatic carcinoma with prostate specific antigen. J. Urol., part 2, 147: 841, 1992.
28. Boring, C. C., Squires, T. S., Tong, T. and Montgomery, S.: Cancer statistics, 1994. CA, 44: 7, 1994.
29. Oesterling, J. E., Martin, S. K., Bergstrahl, E. J. and Lowe, F. C.: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A., 269: 57, 1993.
30. Chybowski, F. M., Larson Keller, J. J., Bergstrahl, E. J. and Oesterling, J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol., 145: 313, 1991.
31. Gleave, M. E., Coupland, D., Drachenberg, D., Cohen, L., Kwong, S., Goldenberg, S. L. and Sullivan, L. D.: Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology, 47: 708, 1996.
32. Schiebler, M. I., Schnall, M. D., Pollack, H. M., Lenkinski, R. E., Tomaszewski, J. E., Wein, A. J., Whittington, R., Rauschning, W. and Kressel, H. Y.: Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology, 189: 339, 1993.
33. Chelsky, M. J., Schnall, M. D., Seidmon, E. J. and Pollack, H. M.: Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J. Urol., 150: 391, 1993.
34. White, S., Hricak, H., Forstner, R., Kurhanewicz, J., Vigneron, D. B., Zaloudek, C. J., Weiss, J. M., Narayan, P. and Carroll, P. R.: Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology, 195: 385, 1995.
35. Quinn, S. F., Franzini, D. A., Demlow, T. A., Rosencrantz, D. R., Kim, J., Hanna, R. M. and Szumowski, J.: MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. Radiology, 190: 323, 1994.
36. Perrotti, M., Kaufman, R. P., Jr., Jennings, T. A., Thaler, H. T., Soloway, S. M., Rifkin, M. D. and Fisher, H. A. G.: Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J. Urol., 156: 106, 1996.
37. Terris, M. K., Pham, T. Q., Issa, M. M. and Kabalin, J. N.: Routine transition zone and seminal vesical biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J. Urol., 157: 204, 1997.
38. Eskew, L. A., Bare, R. L. and McCullough, D. L.: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol., 157: 199, 1997.
39. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
40. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Welsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
41. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
42. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
43. Gerber, G. S., Thisted, R. A., Scardino, P. T., Frohmuller, H. G., Schroeder, F. H., Paulson, D. F., Middleton, A. W., Jr., Rukstalis, D. B., Smith, J. A., Jr., Schellhammer, P. F., Ohori, M. and Chodak, G. W.: Results of radical prostatectomy in men with clinically localized prostate cancer. J.A.M.A., 276: 615, 1996.
44. Sogani, P. C., Isael, A., Lieberman, P. H., Lesser, M. L. and Whitmore, W. F., Jr.: Gleason grading of prostate cancer: a predictor of survival. Urol., 25: 223, 1985.
45. Kramer, S. A., Spahr, J., Brendler, C. B., Glenn, J. F., and Paulson, D. F.: Experience with Gleason's histopathologic grading in prostate cancer. J. Urol., 124: 223, 1980.
46. Partin, A. W., Lee, B. R., Carmichael, M., Walsh, P. C. and Epstein, J. I.: Radical prostatectomy for high grade disease: a reevaluation 1994. J. Urol., 151: 1583, 1994.
47. Olsson, C. A.: Staging lymphadenectomy should be an antecedent to treatment in localized prostatic carcinoma. Urology, 25: 4, 1985.
48. Aihara, M., Lebovitz, R. M., Wheeler, T. M., Kinner, B. M., Ohori, M. and Scardino, P. T.: Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J. Urol., 151: 1558, 1994.
49. Felch, W. C.: Bridging the gap between research and practice. The role of continuing medical education. J.A.M.A., 277: 155, 1997.